| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
MARSEILLE, France & HOUSTON—Vect-Horus and RadioMedix have announced the signing of a letter of intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of glioblastoma multiforme (GBM). This partnership plans to marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans, and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and clinical trials with radiopharmaceuticals.
 
“We look forward to very compelling outcomes from our co-development project, as we seek to create new technologies for the benefit of cancer patients, by giving doctors and hospitals more imaging and treatment options,” said Dr. Jamal Temsamani, director of drug development at Vect-Horus.
 
“RadioMedix has strong interests and all expertise needed to develop the VECTrans–based radio-theranostic agents for GBM,” added Izabela Tworowska, Ph.D., CSO of RadioMedix. “Targeting LDLR can improve the blood brain barrier (BBB) permeability of the drug and selectively deliver the isotope payload to GBM cancer cells.”
 
GBM is the most common and most aggressive malignant type of primary brain tumors, and is a serious and life-threatening condition. The theranostic agent targets the low-density lipoprotein receptor (LDLR), which is highly expressed on many cancer cells, including glioblastoma. Positron emission tomography (PET) imaging and biodistribution studies in human glioblastoma xenograft and orthotopic models have shown a significant accumulation of the agent within the tumor.
 
“Development of a highly sensitive and effective theranostic approach for GBM has always been among our top priorities. Our initial evaluation of VECTrans technology appears to be extremely promising,” noted Dr. Ebrahim Delpassand, CEO of RadioMedix. “Our plan is to utilize VECTrans technology to initially develop an accurate molecular diagnostic PET/CT probe to precisely map the tumor involvement in the brain. This will significantly improve precision of the surgical resection of the tumor. The treatment will then be followed by targeted alpha-emitter or beta-emitter radionuclide therapy using the same technology to eradicate any residual malignant cells at the molecular level.”
 
“We are pleased that our technology, VECTrans in combination with expertise of RadioMedix will serve to advance an innovative and promising approach for glioblastoma treatment,” expressed Alexandre Tokay, CEO of Vect-Horus. “This co-development project is fully aligned with our strategy to expand the use of our technology in cancer indications with high unmet medical needs.”

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue